Drugmaker Vectura's H1 revenue up 6 pct on rising sales of inhaled products
Sept 6 - Vectura said revenue rose 6 percent in the first half of the year, driven by rising sales of its recently launched inhaled products and the continued weakness of sterling against a basket of its main trading currencies.
The FTSE-250 firm that specializes in developing lung drugs said revenue rose to 78.8 million pounds ($102.67 million) in the six months ended June 30 from 73.9 million pounds in the prior-year period.
The company posted a higher loss before tax of 44.5 million pounds, up from a loss of 22.4 million pounds earlier, as amortisation expenses continued to increase following its merger with SkyePharma (LSE: 4547152.L - news) in June.
($1 = 0.7675 pounds) (Reporting by Justin George Varghese in Bengaluru, editing by Louise Heavens)